Company
Headquarters: Beijing, China
Employees: 2,934
CN¥26.37 Billion
CNY as of July 1, 2024
US$3.63 Billion
Company | Market Cap (USD) |
---|---|
Intuitive | $154.23 B |
EssilorLuxottica SA | $98.99 B |
Becton, Dickinson and Company | $65.82 B |
Alcon Inc. | $43.72 B |
HOYA Corp | $42.76 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and commercialization insulin and its analogues primarily in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro; Raplin, an insulin aspart injection; and Raplin 30, an insulin aspart 30 injection, as well as medical devices. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Gan & Lee Pharmaceuticals Co. Ltd has the following listings and related stock indices.
Stock: SSE: 603087 wb_incandescent